MedTrace Logo

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

NCT00432315 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-09-14

No results posted yet for this study

Summary

Primary objective:

• To assess the response rate to induction therapy with docetaxel/CDDP.

Secondary objectives:

To assess

* Resectability after induction therapy
* Time to progression
* Overall survival
* Safety profile
* Quality of Life

Conditions

  • Carcinoma, Squamous Cell

Interventions

DRUG

Docetaxel + CDDP

* 3 cycles chemotherapy : docetaxel + CDDP * Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered) * 3 cycles adjuvant chemotherapy docetaxel

DRUG

docetaxel + CDDP

* 3 cycles chemotherapy: docetaxel + CDDP * Radiochemotherapy * 3 cycles adjuvant chemotherapy docetaxel

Sponsors & Collaborators

Principal Investigators

  • Alexandra Edlmayer, Dr. · Sanofi

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00432315 on ClinicalTrials.gov